PRESTIGE CONSUMER HEALTHCARE INC. M a r c h 7 , 2 0 2 4
CAGNY Luncheon Presentation
Safe Harbor Disclosure
This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, diluted EPS, leverage, free cash flow, and organic revenue growth; the Company's ability to execute on its brand-building strategy; the expected market share and consumption trends for the Company's brands; and the Company's ability to reduce debt and execute on its disciplined capital allocation strategy, including debt reduction. Words such as "trend," "continue," "will," "expect," "project," "may," "should," "could," "would," and similar
expressions identify forward-looking statements. Such forward-looking statements represent the Company's expectations and beliefs and involve a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include, among others, the impact of high inflation, interest rates, global supply chain constraints and geopolitical instability, including on economic and business conditions, consumer trends, retail management initiatives, and disruptions to the manufacturing, distribution and supply chain and related price increases; labor shortages; competitive pressures; the impact of the Company's advertising and promotional and new product development initiatives; customer inventory management initiatives; the ability to pass along rising costs to customers without impacting sales; fluctuating foreign exchange
rates; and other risks set forth in Part I, Item 1A. Risk Factors in the Company's Annual Report on Form 10-K for the year ended March
31, 2023. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation. Except to the extent required by applicable law, the Company undertakes no obligation to update any forward-looking statement contained in this presentation, whether as a result of new information, future events, or otherwise.
All adjusted GAAP numbers presented are footnoted and reconciled to their closest GAAP measurement in the attached reconciliation schedules or in our February 8, 2024 earnings release in the "About Non-GAAP Financial Measures" section.
C A G N Y P R E S E N T A T I O N M A R C H 2 0 2 4
Contents Overview
- Introduction to Prestige Consumer Healthcare
II. Brand-Building Playbook
- Financial Strategy & Capital Allocation IV. The Road Ahead
C A G N Y P R E S E N T A T I O N M A R C H 2 0 2 4 | 3 |
- Introduction to Prestige Consumer Healthcare
C A G N Y P R E S E N T A T I O N M A R C H 2 0 2 4
Who We Are: Helping Consumers Care for Themselves
eye drops per year
throat drops for every cold season
doses of pain relief per week
infections treated annually
C A G N Y P R E S E N T A T I O N M A R C H 2 0 2 4 | 5 |
Diversified Portfolio of Leading Consumer Healthcare Brands
Total Sales by Category
Diverse Portfolio of Market-Leading Brands
Oral
Care
Analgesics
9%
11%
Skin
Care 11%
Women's
Health
23%
Feminine Hygiene
Vaginal Anti-Fungal
Rehydration
Motion Sickness
Allergy & Redness Relief Drop Dry Eye Relief Treatment
Cough /
Cold
11%
15%
Eye &
Ear Care
20%
GI
Sore Throat Liquids/Lozenge
Wart Removal Lice/Parasite Treatment
Powdered Analgesic
FY 23 Revenues; Other OTC not shown (less than 1%)
C A G N Y P R E S E N T A T I O N M A R C H 2 0 2 4 | 6 |
Proven Strategy Delivers Long-Term Performance
1
2
3
Proven Ability to Execute Value Creation Strategy
Investing for Growth with Proven Brand-Building Playbook
Superior Business Attributes Drive Strong Free Cash Flow
Scalable & Efficient Platform Enables Capital Allocation Optionality
+5.4% | +3.5% | +12.4% |
3-Yr CAGR | 3-Yr CAGR | 3-Yr CAGR |
Revenue | Organic Growth(1) | Adj. EPS(3) |
C A G N Y P R E S E N T A T I O N M A R C H 2 0 2 4 | 7 |
II. Brand-building
Playbook
C A G N Y P R E S E N T A T I O N M A R C H 2 0 2 4
Brand-Building Focus Positions Us for Long-Term Growth
Understanding Consumer Insights and Opportunity
2 Flexible & Agile Brand Strategies in a Dynamic Environment
3 E-Commerce Success through Investments
4 Proven New Product Development
Result: Long-Term Success & Differentiation Across Channels & Categories
C A G N Y P R E S E N T A T I O N M A R C H 2 0 2 4 | 9 |
Dramamine: Thinking Beyond Motion Sickness
Broadened Motion Sickness Offering | Expanding an Iconic Brand into Nausea |
Robust Digital Campaigns
Supporting Brand
2011
New Forms
& Flavors
#1 Brand* in Motion Sickness | Leading brand* in Nausea |
Successful Brand Building Resulting in Approximate +8% 10-Year Sales CAGR*
* Market Share and CAGR rate reflects U.S. IRI MULO + C store for the 52 weeks ended 1-1-23
C A G N Y P R E S E N T A T I O N M A R C H 2 0 2 4 | 10 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Prestige Consumer Healthcare Inc. published this content on 06 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 March 2024 15:41:02 UTC.
